Safety and Efficacy of Vitreous Delineating Agent During Vitrectomy
- Conditions
- Vitrectomy
- Interventions
- Registration Number
- NCT00532415
- Lead Sponsor
- Alcon Research
- Brief Summary
The purpose of this study is to evaluate the safety and efficacy of triamcinolone acetonide suspension when used for visualization of structures in the back of the eye during eye surgery.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
- Patients planning to undergo pars plana vitrectomy with good vision in the non-surgery eye.
- Other protocol-defined inclusion criteria may apply.
- Patients under 18.
- Patients with previous vitrectomy, elevated intraocular pressure (IOP) and/or history of ocular inflammatory disease.
- Other protocol-defined exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Triamcinolone Triamcinolone Acetonide Injectable Suspension Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal.
- Primary Outcome Measures
Name Time Method Change in Mean Visualization Score at Post-Instillation from Pre-Instillation Day 0 A video image of the posterior segment structures of the eye was taken before instillation of the test product and after. An independent masked reader evaluated the images and graded the degree of visualization on a 5-point scale ranging from 1 to 4 and anchored at the ends by "Not Visible (0)" and "Clearly Delineated (4)." The mean difference was calculated, and a higher number indicated increased visibility.
- Secondary Outcome Measures
Name Time Method